Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNTECH, INC.	-.--%	-.--%	-	-	1.16K
LONZA GROUP AG	+0.81%	+0.96%	-11.29%	-9.84%	42.75B
REVOLUTION MEDICINES, INC.	+3.31%	+9.22%	+308.19%	+562.02%	34.65B
BEONE MEDICINES AG	+2.84%	+3.80%	+6.87%	+34.93%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.34%	+8.51%	-22.34%	28B
CELLTRION, INC.	-0.57%	+4.45%	+12.31%	+20.42%	24.83B
ASCENDIS PHARMA A/S	-0.14%	+7.06%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-3.13%	+52.04%	+107.47%	13.14B
EUROFINS SCIENTIFIC SE	-0.22%	-2.09%	+5.55%	+4.57%	12.61B
IONIS PHARMACEUTICALS, INC.	-0.26%	+0.41%	+100.27%	+80.69%	12.25B
Average	+0.48%	+0.89%	+60.31%	+97.24%	23.62B
Weighted average by Cap.	+0.82%	+1.27%	+65.21%	+113.20%

See all sector performances

BioSyntech, Inc. is a Canada-based biotechnology company. The Company is developing biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The Company's platform technology is a family of hydrogels called BST-Gel, some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offers properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. The Company's lead, late-stage product, BST-CarGel is undergoing an international pivotal trial.

Employees

Sector

Biotechnology & Medical Research

More about the company